RESEARCH ARTICLE Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in

Objective To evaluate concurrent chemotherapy for T4 classification nasopharyngeal carcinoma (NPC) treated by intensity-modulated radiotherapy (IMRT). Methods From July 2004 to June 2011, 180 non-metastatic T4 classification NPC patients were retro-spectively analyzed. Of these patients, 117 patients were treated by concurrent chemora-diotherapy (CCRT) using IMRT and 63 cases were treated by IMRT alone. Results The median follow-up time was 58.97 months (range, 2.79–114.92) months. For all the pa-tients, the 1, 3 and 5-year local failure-free survival (LFFS) rates were 97.7%, 89.2 % and 85.9%, regional failure free survival (RFFS) rates were 98.9%, 94.4 % and 94.4%, distant failure-free survival (DFFS) rates were 89.7%, 79.9 % and 76.2%, and overall survival (OS) rates were 92.7%, 78.9 % and 65.3%, respectively. No statistically significant difference wa